BiotechTube

Grazoprevir plus Elbasvir

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hepatitis C Viral

Conditions

Hepatitis C Viral, Chronic Kidney Disease stage3

Trial Timeline

Apr 1, 2017 → Sep 20, 2018

NCT ID
NCT03144635

About Grazoprevir plus Elbasvir

Grazoprevir plus Elbasvir is a approved stage product being developed by Merck for Hepatitis C Viral. The current trial status is completed. This product is registered under clinical trial identifier NCT03144635. Target conditions include Hepatitis C Viral, Chronic Kidney Disease stage3.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT03144635ApprovedCompleted

Competing Products

20 competing products in Hepatitis C Viral

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
47
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
49
TERN-101Terns PharmaceuticalsPhase 2
49
TERN-201Terns PharmaceuticalsPhase 1
30
IVA337 + IVA337 + PlaceboInventivaPhase 2
47
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
47
IVA337 + PlaceboInventivaPhase 3
72
Pegasys® + Pegasys®Chugai PharmaceuticalApproved
85
peginterferon alfa-2a + rivavirinChugai PharmaceuticalPhase 3
77
SOF + COPEChugai PharmaceuticalPre-clinical
23
Colesevelam HclDaiichi SankyoPhase 2
52
ASP9831 + PlaceboAstellas PharmaPhase 2
52
FK788Astellas PharmaPhase 2
52
MK-2248MerckPhase 1
33
Interferon alfacon-1Astellas PharmaPhase 3
77
Pegylated Interferon + RibavirinAstellas PharmaApproved
85
Tacrolimus + steroids, monoclonal anti-IL2R antibodyAstellas PharmaPhase 2
52
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
33
Dolutegravir + MethadoneShionogiPhase 1
33
Clevudine + AdefovirEisaiPhase 3
77

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85